Download MendeleyStructure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
Smith, A.L., D'Angelo, N.D., Bo, Y.Y., Booker, S.K., Cee, V.J., Herberich, B., Hong, F.T., Jackson, C.L., Lanman, B.A., Liu, L., Nishimura, N., Pettus, L.H., Reed, A.B., Tadesse, S., Tamayo, N.A., Wurz, R.P., Yang, K., Andrews, K.L., Whittington, D.A., McCarter, J.D., Miguel, T.S., Zalameda, L., Jiang, J., Subramanian, R., Mullady, E.L., Caenepeel, S., Freeman, D.J., Wang, L., Zhang, N., Wu, T., Hughes, P.E., Norman, M.H.(2012) J Med Chem 55: 5188-5219
- PubMed: 22548365 Search on PubMed
- DOI: https://doi.org/10.1021/jm300184s
- Primary Citation Related Structures:
4DK5 - PubMed Abstract:
A highly selective series of inhibitors of the class I phosphatidylinositol 3-kinases (PI3Ks) has been designed and synthesized. Starting from the dual PI3K/mTOR inhibitor 5, a structure-based approach was used to improve potency and selectivity, resulting in the identification of 54 as a potent inhibitor of the class I PI3Ks with excellent selectivity over mTOR, related phosphatidylinositol kinases, and a broad panel of protein kinases. Compound 54 demonstrated a robust PD-PK relationship inhibiting the PI3K/Akt pathway in vivo in a mouse model, and it potently inhibited tumor growth in a U-87 MG xenograft model with an activated PI3K/Akt pathway.
- Department of Medicinal Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799, United States. adrians@amgen.com
Organizational Affiliation:
